-
1
-
-
47249092413
-
MPL mutations in myeloproliferative disorders: Analysis of the PT-1 cohort
-
Beer P. A., Campbell P. J., Scott L. M., Bench A. J., Erber W. N., Bareford D., Wilkins B. S., Reilly J. T., Hasselbalch H. C., Bowman R., Wheatley K., Buck G., Harrison C. N. & Green A. R. (2008) MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 112, 141-149.
-
(2008)
Blood
, vol.112
, pp. 141-149
-
-
Beer, P.A.1
Campbell, P.J.2
Scott, L.M.3
Bench, A.J.4
Erber, W.N.5
Bareford, D.6
Wilkins, B.S.7
Reilly, J.T.8
Hasselbalch, H.C.9
Bowman, R.10
Wheatley, K.11
Buck, G.12
Harrison, C.N.13
Green, A.R.14
-
2
-
-
65349170996
-
Mutations in the JAK2 and MPL genes and their correlation to clinical parameters in patients with chronic myeloproliferative disease
-
Bojko P., Abenhardt W., Schnittger S. & Haferlach T. (2009) Mutations in the JAK2 and MPL genes and their correlation to clinical parameters in patients with chronic myeloproliferative disease. Onkologie 32, 191-195.
-
(2009)
Onkologie
, vol.32
, pp. 191-195
-
-
Bojko, P.1
Abenhardt, W.2
Schnittger, S.3
Haferlach, T.4
-
3
-
-
66249137734
-
Mutation in TET2 in myeloid cancers
-
Delhommeau F., Dupont S., Valle V. D., James C., Trannoy S., Masse A., Kosmider O., Le Couedic J. P., Robert F., Alberdi A., Lecluse Y., Plo I., Dreyfus F. J., Marzac C., Casadevall N., Lacombe C., Romana S. P., Dessen P., Soulier J., Viguie F., Fontenay M., Vainchenker W. & Bernard O. A. (2009) Mutation in TET2 in myeloid cancers. New England Journal of Medicine 360, 2289-2301.
-
(2009)
New England Journal of Medicine
, vol.360
, pp. 2289-2301
-
-
Delhommeau, F.1
Dupont, S.2
Valle, V.D.3
James, C.4
Trannoy, S.5
Masse, A.6
Kosmider, O.7
Le Couedic, J.P.8
Robert, F.9
Alberdi, A.10
Lecluse, Y.11
Plo, I.12
Dreyfus, F.J.13
Marzac, C.14
Casadevall, N.15
Lacombe, C.16
Romana, S.P.17
Dessen, P.18
Soulier, J.19
Viguie, F.20
Fontenay, M.21
Vainchenker, W.22
Bernard, O.A.23
more..
-
4
-
-
40749152298
-
MassARRAY assay: A more accurate method for JAK2V617F mutation detection in Chinese patients with myeloproliferative disorders
-
Fu J. F., Shi J. Y., Zhao W. L., Li G., Pan Q., Li J. M., Hu J., Shen Z. X., Jin J., Chen F. Y. & Chen S. J. (2008) MassARRAY assay: a more accurate method for JAK2V617F mutation detection in Chinese patients with myeloproliferative disorders. Leukemia 22, 660-663.
-
(2008)
Leukemia
, vol.22
, pp. 660-663
-
-
Fu, J.F.1
Shi, J.Y.2
Zhao, W.L.3
Li, G.4
Pan, Q.5
Li, J.M.6
Hu, J.7
Shen, Z.X.8
Jin, J.9
Chen, F.Y.10
Chen, S.J.11
-
5
-
-
54149085320
-
JAK2 and MPL mutations in myeloproliferative neoplasms: Discovery and science
-
Kilpivaara O. & Levine R. L. (2008) JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. Leukemia 22, 1813-1817.
-
(2008)
Leukemia
, vol.22
, pp. 1813-1817
-
-
Kilpivaara, O.1
Levine, R.L.2
-
6
-
-
63449127583
-
A germline JAK2 SNP is associated with predisposition to the development of JAK2 (V617F)-positive myeloproliferative neoplasms
-
Kilpivaara O., Mukherjee S., Schram A. M., Wadleigh M., Mullally A., Ebert B. L., Bass A., Marubayashi S., Heguy A., Garcia-Manero G., Kantarjian H., Offit K., Stone R. M., Gilliland D. G., Klein R. J. & Levine R. L. (2009) A germline JAK2 SNP is associated with predisposition to the development of JAK2 (V617F)-positive myeloproliferative neoplasms. Nature Genetics 41, 455-459.
-
(2009)
Nature Genetics
, vol.41
, pp. 455-459
-
-
Kilpivaara, O.1
Mukherjee, S.2
Schram, A.M.3
Wadleigh, M.4
Mullally, A.5
Ebert, B.L.6
Bass, A.7
Marubayashi, S.8
Heguy, A.9
Garcia-Manero, G.10
Kantarjian, H.11
Offit, K.12
Stone, R.M.13
Gilliland, D.G.14
Klein, R.J.15
Levine, R.L.16
-
7
-
-
33750534561
-
MPL515 mutations in myeloproliferative and other myeloid disorders: A study of 1182 patients
-
Pardanani A. D., Levine R. L., Lasho T., Pikman Y., Mesa R. A., Wadleigh M., Steensma D. P., Elliott M. A., Wolanskyj A. P., Hogan W. J., McClure R. F., Litzow M. R., Gilliland D. G. & Tefferi A. (2006) MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108, 3472-3476.
-
(2006)
Blood
, vol.108
, pp. 3472-3476
-
-
Pardanani, A.D.1
Levine, R.L.2
Lasho, T.3
Pikman, Y.4
Mesa, R.A.5
Wadleigh, M.6
Steensma, D.P.7
Elliott, M.A.8
Wolanskyj, A.P.9
Hogan, W.J.10
McClure, R.F.11
Litzow, M.R.12
Gilliland, D.G.13
Tefferi, A.14
-
8
-
-
41949128334
-
Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders
-
Pardanani A., Fridley B. L., Lasho T. L., Gilliland D. G. & Tefferi A. (2008) Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood 111, 2785-2789.
-
(2008)
Blood
, vol.111
, pp. 2785-2789
-
-
Pardanani, A.1
Fridley, B.L.2
Lasho, T.L.3
Gilliland, D.G.4
Tefferi, A.5
-
9
-
-
33746437130
-
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia
-
Pikman Y., Lee B. H., Mercher T., McDowell E., Ebert B. L., Gozo M., Cuker A., Wernig G., Moore S., Galinsky I., De-Angelo D. J., Clark J. J., Lee S. J., Golub T. R., Wadleigh M., Gilliland D. G. & Levine R. L. (2006) MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Medicine 3, 1140-1151.
-
(2006)
PLoS Medicine
, vol.3
, pp. 1140-1151
-
-
Pikman, Y.1
Lee, B.H.2
Mercher, T.3
McDowell, E.4
Ebert, B.L.5
Gozo, M.6
Cuker, A.7
Wernig, G.8
Moore, S.9
Galinsky, I.10
De-Angelo, D.J.11
Clark, J.J.12
Lee, S.J.13
Golub, T.R.14
Wadleigh, M.15
Gilliland, D.G.16
Levine, R.L.17
-
10
-
-
48749127301
-
Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia
-
Ricksten A., Palmqvist L., Johansson P. & Andreasson B. (2008) Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia. Haematologica 93, 1260.
-
(2008)
Haematologica
, vol.93
, pp. 1260
-
-
Ricksten, A.1
Palmqvist, L.2
Johansson, P.3
Andreasson, B.4
-
11
-
-
33749358349
-
Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia
-
Scott L. M., Scott M. A., Campbell P. J. & Green A. R. (2006) Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 108, 2435-2437.
-
(2006)
Blood
, vol.108
, pp. 2435-2437
-
-
Scott, L.M.1
Scott, M.A.2
Campbell, P.J.3
Green, A.R.4
-
12
-
-
33846660947
-
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
-
Scott L. M., Tong W., Levine R. L., Scott M. A., Beer P. A., Stratton M. R., Futreal P. A., Erber W. N., McMullin M. F., Harrison C. N., Warren A. J., Gilliland D. G., Lodish H. F. & Green A. R. (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. New England Journal of Medicine 356, 459-468.
-
(2007)
New England Journal of Medicine
, vol.356
, pp. 459-468
-
-
Scott, L.M.1
Tong, W.2
Levine, R.L.3
Scott, M.A.4
Beer, P.A.5
Stratton, M.R.6
Futreal, P.A.7
Erber, W.N.8
McMullin, M.F.9
Harrison, C.N.10
Warren, A.J.11
Gilliland, D.G.12
Lodish, H.F.13
Green, A.R.14
-
13
-
-
43449106506
-
The Janus kinase 2 (JAK2) V617F mutation in Chinese patients with chronic myeloproliferative disorders
-
Xiao Z., Zhang Y., Li L., Nie L., Yang L. & Xu S. (2008) The Janus kinase 2 (JAK2) V617F mutation in Chinese patients with chronic myeloproliferative disorders. Haematologica 93, 787-788.
-
(2008)
Haematologica
, vol.93
, pp. 787-788
-
-
Xiao, Z.1
Zhang, Y.2
Li, L.3
Nie, L.4
Yang, L.5
Xu, S.6
-
14
-
-
42049095136
-
JAK2 V617F patients with essential thrombocythemia presented with clinical features of polycythemia vera
-
Zhang S. J., Qiu H. X., Fischer B. S., Li W., Duan L., Sun X., Xu W. & Li J. (2008) JAK2 V617F patients with essential thrombocythemia presented with clinical features of polycythemia vera. Leukaemia & Lymphoma 49, 696-699.
-
(2008)
Leukaemia & Lymphoma
, vol.49
, pp. 696-699
-
-
Zhang, S.J.1
Qiu, H.X.2
Fischer, B.S.3
Li, W.4
Duan, L.5
Sun, X.6
Xu, W.7
Li, J.8
|